Edition:
India

Tetraphase Pharmaceuticals Inc (TTPH.OQ)

TTPH.OQ on NASDAQ Stock Exchange Global Select Market

6.34USD
19 Jan 2018
Change (% chg)

$0.03 (+0.48%)
Prev Close
$6.31
Open
$6.27
Day's High
$6.41
Day's Low
$6.18
Volume
101,480
Avg. Vol
184,163
52-wk High
$9.69
52-wk Low
$3.59

Select another date:

Wed, Jan 3 2018

BRIEF-Tetraphase Pharmaceuticals Announces Submission Of NDA To FDA For Eravacycline To Treat Intra-Abdominal Infections

* TETRAPHASE PHARMACEUTICALS ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION TO FDA FOR ERAVACYCLINE FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI)

BRIEF-Millennium Management Llc Reports 5.3 Pct Passive Stake In Tetraphase Pharmaceuticals As On Dec 14

* MILLENNIUM MANAGEMENT LLC REPORTS 5.3 PERCENT PASSIVE STAKE IN TETRAPHASE PHARMACEUTICALS AS ON DEC 14 - SEC FILING Source text: (http://bit.ly/2kt52WQ) Further company coverage:

BRIEF-Tetraphase Pharmaceuticals Q3 loss per share $0.63

* Tetraphase pharmaceuticals reports third quarter 2017 financial results and highlights recent clinical and corporate achievements

BRIEF-Tetraphase Pharmaceuticals signs commercial supply agreement with Finorga

* Tetraphase Pharmaceuticals Inc says ‍on October 16 co and finorga sas entered into a commercial supply agreement​ - sec filing

BRIEF-TETRAPHASE PHARMACEUTICALS APPOINTS KAM UNNINAYAR AS CFO

* TETRAPHASE PHARMACEUTICALS APPOINTS KAM UNNINAYAR AS CHIEF FINANCIAL OFFICER

BRIEF-Tetraphase Pharmaceuticals presents clinical data from oral eravacycline development program at IDWEEK 2017​

* Tetraphase Pharmaceuticals - ‍phase 2 trial in patients with complicated urinary tract infections expected to begin in h1 2018​

BRIEF-Tetraphase Pharmaceuticals completes enrollment of ignite3 phase 3 clinical trial of eravacycline

* Tetraphase Pharmaceuticals completes enrollment of ignite3 phase 3 clinical trial of eravacycline in complicated urinary tract infections

BRIEF-Tetraphase announces validation of IV eravacycline MAA by European Medicines Agency

* Tetraphase Pharmaceuticals announces submission and validation of IV eravacycline marketing authorization application by European Medicines Agency

BRIEF-Tetraphase announces pricing of public offering of common stock

* Tetraphase announces pricing of public offering of common stock

BRIEF-Tetraphase announces proposed public offering of common stock

* Tetraphase announces proposed public offering of common stock

Select another date: